A black-tie gathering aboard a decommissioned World War II cargo ship in San Francisco offered guests free peptide samples after they signed liability waivers. The event brought a consumer-facing display to an interim federal policy that is narrower than an approval of the products or a general authorization to compound them.
On Oct. 30, the Department of Health and Human Services said it did not intend to pursue enforcement against certain section 503A compounding involving BPC-157, TB-500, KPV, Epitalon, Semax and MOTS-C while the relevant bulk-substance list is developed through rulemaking. The Federal Register notice describes the policy as interim; it does not make the peptides FDA-approved medicines.
A temporary enforcement policy, not a drug approval
The distinction matters because compounded drugs are not FDA-approved and are not reviewed by the agency for safety, effectiveness or quality before marketing, the notice says. It also says the draft policy creates no rights, is not binding on HHS or the public, and may be revisited if a safety signal or product-quality issue arises. The interim policy concerns section 503A compounding while the bulk-substance list is developed through rulemaking.
What the interim policy does—and does not—cover
The policy concerns certain section 503A compounding by state-licensed pharmacies, federal facilities and licensed physicians; it is not a general authorization for peptide products or a policy for 503B outsourcing facilities or direct sales of research chemicals, according to the Federal Register notice. Outside this interim enforcement policy, FDA says 503A compounders may use bulk drug substances only under specified conditions, including compliance with an applicable USP or NF monograph when one exists, or inclusion on the 503A bulks list when the other listed conditions apply. A separate FDA case illustrates why a research-use-only label is not conclusive: in a December 2024 warning letter to Summit Research Peptides, which listed an address in Hoover, Alabama, FDA said website evidence showed the company’s semaglutide and other products were intended for human use despite such labeling. The warning letter involved a different company and different products from those described at the San Francisco event, according to FDA.
The shipboard event and the gap between labels and use
The San Francisco Standard reported that Haus Fund held the gathering aboard the S.S. Jeremiah O’Brien, docked near Fisherman’s Wharf, and offered samples after attendees signed waivers. The Los Angeles Times reported that the waivers acknowledged possible risks but did not mention that some products were labeled for research use only. That label alone does not establish that a product is suitable for human consumption.
The Los Angeles Times reported that one sample was a dissolving strip from Afterglow Science containing BPC-157 and TB-500. Its packets were marked “for research use only,” and a company co-founder told the newspaper that the effectiveness of oral peptides was unknown.
The gathering also included topical GHK-Cu, which the Los Angeles Times described as a legal cosmetic ingredient. That is distinct from injectable or compounded forms covered by the policy discussion. The event’s products and samples should therefore not be read as a direct measure of what the federal policy permits.
Interest is growing faster than the human evidence
The event took place amid increased attention to BPC-157. The Verge reported that BPC-157 videos on YouTube and TikTok drew more than 50 million views in 2024. An AJMC headline described BPC-157 use as having risen 33-fold. A rise in use does not by itself show that the compound caused reported improvements or how widespread use is.
The evidence remains limited. A 2025 systematic review identified 35 preclinical studies and one human clinical study of BPC-157, The Verge reported. AJMC characterized the evidence as scant. TB-500 is also among the peptides covered by the interim policy.
Regulatory and medical experts cited by the Los Angeles Times warned that the policy could widen access to products without established human safety or effectiveness. Supporters argue that compounding may provide an alternative to a gray market where products can have uncertain sourcing or quality. Neither position resolves the central evidence gap: the current policy is an enforcement choice, not a finding that these peptides work, are safe, or are effective in the forms being offered to consumers.
